- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00129532
Trial of SAVVY and HIV in Ghana
September 7, 2005 updated by: Biosyn
Randomized Controlled Trial of SAVVY and HIV in Ghana
Heterosexual contact is now the primary route of transmission for HIV worldwide.
This study is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk.
Study Overview
Detailed Description
Heterosexual contact is now the primary route of transmission for HIV worldwide.
This study is a phase 3 multi-center, fully-masked, randomized, placebo controlled trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk.
Study Type
Interventional
Enrollment
2142
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Accra, Ghana
- Noguchi Memorial Institute for Medical Research/University of Ghana
-
Kumasi, Ghana
- Komfo Anokye Teaching Hospital/Kwame Nkrumah University of Science and Technology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- 18 to 35 year old women
- HIV negative
- More than one sexual partner in past 3 months
- Average of 3 coital acts per week
- Willing to use vaginal gel and condoms for 12 months
Exclusion Criteria:
- HIV positive
- Pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
combined incidence of HIV-1 and HIV-2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Leigh Peterson, PhD, FHI 360
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2004
Study Registration Dates
First Submitted
August 11, 2005
First Submitted That Met QC Criteria
August 11, 2005
First Posted (Estimate)
August 12, 2005
Study Record Updates
Last Update Posted (Estimate)
September 8, 2005
Last Update Submitted That Met QC Criteria
September 7, 2005
Last Verified
August 1, 2005
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9779
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on 1.0% C31G SAVVY vaginal gel
-
BiosynUnited States Agency for International Development (USAID); FHI 360Unknown
-
TR TherapeuticsCompleted
-
Università degli Studi dell'InsubriaUnknown
-
DermBiont, Inc.Active, not recruitingA Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic KeratosisSeborrheic KeratosisUnited States
-
Starpharma Pty LtdCompletedBacterial VaginosisUnited States
-
DermBiont, Inc.RecruitingDermatosis Papulosa NigraUnited States
-
BioClin BVAvaniaRecruiting
-
TR TherapeuticsCompleted
-
Procare Health Iberia S.L.Adknoma Health ResearchActive, not recruitingHuman Papilloma Virus Infection | Human Papilloma Virus | Cervix LesionSpain
-
Procare Health Iberia S.L.Adknoma Health ResearchCompletedHPV Infection | Lesion CervixSpain